Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
$STLNF Stallion Uranium Announces Additional Uranium Property Staking, Further Expanding Largest Exploration Land Package in Southwestern Athabasca Basin https://finance.yahoo.com/news/stallion-uranium-announces-additional-uranium-113000019.html
$TWOH STRATEGIC EXPANSION UNVEILED: HOW THE TWOH ACQUISITION PLAYBOOK WILL TRANSFORM FOOD DISTRIBUTION IN CANADA https://twohandsgroup.com/blog/strategic-expansion-twoh-acquisition-playbook
$NRXP News: NRx Pharmaceuticals (NASDAQ:NRXP) Initiates Strategy to Combat Short Sales
Initiative is intended to protect shareholder value through continued compliance with Nasdaq listing rules and elimination of naked short sales positions in the Company's securities
The Company is contemplating a reverse split, if needed to maintain NASDAQ listing compliance, to be accompanied by change in corporate name and CUSIP number
Company has retained former SEC enforcement leadership to notify leading brokerages of the need to close all naked short positions in the Company's securities and to prevent future accumulation of naked short positions in the Company's new security
RADNOR, Pa., March 12, 2024 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company" today initiated actions to combat short sellers in the Company's stock.
The Company announced a proposal to simultaneously change the CUSIP under which the Company's shares are traded, together with changing the name of the Company to NRx Therapeutics, Inc. The Company plans to accompany these actions with a required exchange of the underlying stock certificates. This certificate change is expected to be seamless for those investors holding NRXP shares in electronic form and similarly for investors who may have established short positions in NRXP by borrowing the underlying shares from a registered shareholder. Any party holding a short position in the Company's shares who has not complied with the legal requirement to borrow the underlying shares of stock (i.e. "a naked short" may be unable to exchange that position for a position in the new security.
The Company is working with attorneys who formerly served in leadership positions at the SEC Division of Enforcement to correspond with corporate counsel and compliance heads at leading brokerages to emphasize the current legal prohibitions against naked short sales. As identified in previous announcements, the Company was advised by ShareIntel in September 2023 that substantial naked short positions in the Company's securities had been identified at major brokerage firms.
"We believe it is in the best interests of our shareholders to have fully-compliant trading in the markets," said Janet Rehnquist, Esq., who chairs the Company's Compliance Committee. "As we focus on the development of potentially life-saving drugs to combat suicidal depression, PTSD, and Chronic Pain, it is critical that we take all steps possible to maximize the value of those who have invested in our Company and provided the resources to address these critical unmet medical needs."
About NRx Pharmaceuticals
NRx Pharmaceuticals is a clinical-stage biopharmaceutical company developing therapeutics based on its NMDA platform for the treatment of central nervous system disorders, specifically suicidal bipolar depression, chronic pain and PTSD. The Company is developing NRX-101, an FDA-designated investigational Breakthrough Therapy for suicidal treatment-resistant bipolar depression and chronic pain. NRx has partnered with Alvogen and Lotus around the development and marketing of NRX-101 for the treatment of suicidal bipolar depression. NRX-101 additionally has potential to act as a non-opioid treatment for chronic pain, as well as a treatment for complicated UTI.
NRx has recently announced plans to submit a New Drug Application for HTX-100 (IV ketamine), through Hope Therapeutics, in the treatment of suicidal depression, based on results of well-controlled clinical trials conducted under the auspices of the US National Institutes of Health and newly obtained data from French health authorities, licensed under a data sharing agreement. NRx was awarded Fast Track Designation for development of ketamine (NRX-100) by the US FDA as part of a protocol to treat patients with acute suicidality.
Notice Regarding Forward-Looking Statements
The information contained herein includes forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended. These statements include, among others, statements regarding the proposed public offering and the timing and the use of the proceeds from the offering. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as "may," "will," "should," "would," "expect," "plan," "believe," "intend," "look forward," and other similar expressions among others. These statements relate to future events or to the Company's future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause the Company's actual results to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the Company's control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects the Company's current views with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to the Company's operations, results of operations, growth strategy and liquidity. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's most recent Annual Report on Form 10-K and other filings with the Securities and Exchange Commission. Investors and security holders are urged to read these documents free of charge on the SEC's website at http://www.sec.gov. Except as may be required by applicable law, The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, whether as a result of new information, future events or otherwise.
View original content to download multimedia:https://www.prnewswire.com/news-releases/nrx-pharmaceuticals-nasdaqnrxp-initiates-strategy-to-combat-short-sales-302086668.html
SOURCE NRx Pharmaceuticals, Inc.
REI......TELL......DUO.........................https://stockcharts.com/h-sc/ui?s=DUO&p=W&b=5&g=0&id=p84354014936
https://stockcharts.com/h-sc/ui?s=TELL&p=W&b=5&g=0&id=p84354014936
https://stockcharts.com/h-sc/ui?s=REI&p=W&b=5&g=0&id=p84354014936
$NRXP: NRx Pharmaceuticals (NASDAQ:NRXP) Completes Memorandum of Understanding and Collaborations with Distribution Partners for HTX-100 (IV Ketamine)
Company to receive first allocation of ketamine for sale by month end
Partners preparing to ship IV Ketamine to full range of customers via 503a and 503b pharmacies
NRx Pharmaceuticals and HOPE Therapeutics aim to provide highest quality product available to those in need and assure ongoing supply
Important step toward goal of providing full suite of supply options, to ultimately include an FDA approved, and widely reimbursed, solution for patients and clinics, subject to board approval
RADNOR, Pa., March 11, 2024 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company") and its wholly owned subsidiary HOPE Therapeutics, clinical-stage biopharmaceutical companies, today announced completion of a Memorandum of Understanding with Conversio Health, a national 503a pharmacy, and a strong, ongoing partnership with Nephron Pharmaceuticals, a manufacturer of Ketamine and 503b pharmacy to provide IV Ketamine to patients and clinics across the country, subject to board approval. These are important steps to providing a full suite of ketamine options for customers across the country, and preparation for potential approval of HTX-100 by regulatory authorities worldwide.
(PRNewsfoto/NRx Pharmaceuticals)
(PRNewsfoto/NRx Pharmaceuticals)
The Company has further entered into a business relationship with an organization that currently serves the business needs of more than 100 ketamine clinics nationwide. The Company has been given a target delivery date prior to the end of this month (March 2024) for initial stock of ketamine for sale to licensed end users. Sales are planned to commence once technical and logistical elements are finalized. Details for ordering will be available on our website as soon as they are available. www.hopetherapeutics.com
In contrast to NRx Pharmaceuticals, which is structured as a Biotechnology research and development company, HOPE Therapeutics is structured as a Specialty Pharmaceutical company that aims to supply a variety of therapeutic products to clinics that are treating suicidal depression and PTSD, including both traditional and digital therapeutics.
"We are pleased to be working with two outstanding organizations in Conversio Health and Nephron Pharmaceuticals to provide this important medication to a market in need of a consistent supply of high-quality, FDA- and DEA- compliant IV ketamine," said Matthew Duffy Chief Business Officer of NRx Pharmaceuticals and co-CEO of HOPE Therapeutics. "Importantly, these efforts will provide a strong foundation for expanding our product offering with our planed filing a New Drug Application with the FDA in the coming months, and the potential launch of HTX-100 in early 2025." The NDA filing currently awaits completion of an additional three months of product stability.
About NRx Pharmaceuticals
NRx Pharmaceuticals is a clinical-stage biopharmaceutical company developing therapeutics based on its NMDA platform for the treatment of central nervous system disorders, specifically suicidal bipolar depression, chronic pain and PTSD. The Company is developing NRX-101, an FDA-designated investigational Breakthrough Therapy for suicidal treatment-resistant bipolar depression and chronic pain. NRx has partnered with Alvogen and Lotus around the development and marketing of NRX-101 for the treatment of suicidal bipolar depression. NRX-101 additionally has potential to act as a non-opioid treatment for chronic pain, as well as a treatment for complicated UTI.
NRx has recently announced plans to submit a New Drug Application for HTX-100 (IV ketamine), through HOPE Therapeutics, in the treatment of suicidal depression, based on results of well-controlled clinical trials conducted under the auspices of the US National Institutes of Health and newly obtained data from French health authorities, licensed under a data sharing agreement. NRx was awarded Fast Track Designation for development of ketamine (NRX-100) by the US FDA as part of a protocol to treat patients with acute suicidality.
About HOPE Therapeutics, Inc.
HOPE Therapeutics, Inc. (www.hopetherapeutics.com) is a Specialty Pharmaceutical Company, wholly-owned by NRX Pharmaceuticals focused on development and marketing of an FDA-approved form of intravenous ketamine for the treatment of acute suicidality and depression together with a digital therapeutic-enabled platform designed to augment and preserve the clinical benefit of NMDA-targeted drug therapy.
Notice Regarding Forward-Looking Statements
The information contained herein includes forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended. These statements include, among others, statements regarding the proposed public offering and the timing and the use of the proceeds from the offering. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as "may," "will," "should," "would," "expect," "plan," "believe," "intend," "look forward," and other similar expressions among others. These statements relate to future events or to the Company's future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause the Company's actual results to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the Company's control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects the Company's current views with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to the Company's operations, results of operations, growth strategy and liquidity. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's most recent Annual Report on Form 10-K and other filings with the Securities and Exchange Commission. Investors and security holders are urged to read these documents free of charge on the SEC's website at http://www.sec.gov. Except as may be required by applicable law, The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, whether as a result of new information, future events or otherwise.
Cision
View original content to download multimedia:https://www.prnewswire.com/news-releases/nrx-pharmaceuticals-nasdaqnrxp-completes-memorandum-of-understanding-and-collaborations-with-distribution-partners-for-htx-100-iv-ketamine-302085271.html
SOURCE NRx Pharmaceuticals, Inc.
IHRT.........REI.............TELL..........................https://stockcharts.com/h-sc/ui?s=IHRTx&p=D&yr=0&mn=3&dy=0&id=p11960084343
https://stockcharts.com/h-sc/ui?s=REI&p=D&yr=0&mn=3&dy=0&id=p11960084343
https://stockcharts.com/h-sc/ui?s=TELL&p=D&yr=0&mn=3&dy=0&id=p11960084343
SONX... Here's what the excitement is about..... Sonendo, Inc. (“Sonendo”) (OTCQX: SONX), a leading dental technology company and developer of the GentleWave® System, today announced that it will report financial results for the fourth quarter and full year 2023 after the market close on Monday, March 11th, 2024. Management will host a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its financial results.
Investors interested in listening to the conference call may do so by dialing (833) 470-1428 for domestic callers or (404) 975-4839 for international callers, using access code: 426330. Live audio of the webcast will be available at: https://investor.sonendo.com.
An archived recording will be available on the “Investors” section of the company’s website at: https://investor.sonendo.com. The webcasts will be available for replay for at least 90 days after the event.
$LBRG Undervalued Here! Ladybug Analyst Price Target Average 0.0561 (+274.09% Upside)
https://stockscan.io/stocks/LBRG
The recorded, final version of the **CBS news covering IFUS tonight is out. It was recorded**. The Text version has a link the front page of the IFUS website that features the SGP+(tm) game changer cattle feed. The story is about IFUS SGP+(tm) cattle feed donation to the North Texas cattle owners to help save what is left of their cattle, and the fact that this new super low cost game changer cattle feed is a huge solution to climate change driven disasters like North Texas suffered last week, that destroyed 1.1 Million acres of grass and cattle industry assets.
https://www.wafb.com/2024/03/07/new-innovative-cattle-feed-being-donated-north-texas/
MULN........................................https://stockcharts.com/h-sc/ui?s=MULN&p=W&b=5&g=0&id=p84354014936
$LBRG Acquisitions have diversified revenue streams bringing revenues to almost $6million/Yr !!!
The recent acquisition of Nutra55 is expected to boost revenue by $2.4 million! https://stocktitan.net/news/LBRG/ladybug-announces-acquisition-of-e-commerce-generating-2-4-million-ot3u2ufjcdf0.html
$CBDW Perfect entry zone here @0.03 https://schrts.co/ezqjwGga
$SYNX is proud to announce that it has developed an innovative new product designed for dogs in militaries. https://www.silynxcom.com/silynxcom-unveils-groundbreaking-headset-for-military-dogs-offering-unparalleled-protection-and-communication/
LWLG making internet go faster using less energy
Thats what data centers need
LWLG BUY RATING
LWLG MAKING INTERNET FASTER WITH LESS ENERGY
https://www.lightwavelogic.com/
http://www.washingtonpost.com/business/2024/03/07/ai-data-centers-power/
https://www.americanbulls.com/SignalPage.aspx?lang=en&Ticker=LWLG
SONX....GAME CHANGER **** Sonendo, Inc... conference call for the Report Fourth Quarter and Full Year 2023 Financial Results on March 11, 2024
March 1, 2024
LAGUNA HILLS, Calif.--(BUSINESS WIRE)-- Sonendo, Inc. (“Sonendo”) (OTCQX: SONX), a leading dental technology company and developer of the GentleWave® System, today announced that it will report financial results for the fourth quarter and full year 2023 after the market close on Monday, March 11th, 2024. Management will host a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its financial results.
Investors interested in listening to the conference call may do so by dialing (833) 470-1428 for domestic callers or (404) 975-4839 for international callers, using access code: 426330. Live audio of the webcast will be available at: https://investor.sonendo.com.
$LBRG Ladybug NutraTech's strategic rebranding is underscored by the unveiling of its new website, http://ladybugnutratech.com, marking a significant evolution in the company's business strategy.
$NRXP News: NRx Pharmaceuticals (NASDAQ: NRXP) Announces Last Patient, Last Visit in its Phase 2b/3 Trial of NRX-101 in Suicidal Treatment Resistant Bipolar Depression
Marks a major step in the development of what could be the first drug approved for Suicidal Bipolar Depression
The study database is being cleaned and locked; statistical analysis and top-line data to follow shortly thereafter
Study maintained 95% concordance rate between study sites and central raters on primary endpoint. No unexpected Serious Adverse Events were reported.
Positive data and FDA comment would trigger the next $4 million milestone payment from partners Alvogen and Lotus and their assumption of development costs; agreement provides for up to $329 million in milestone payments and a royalty on Net Sales in the mid-teens
RADNOR, Pa., March 4, 2024 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company, today announced that the 74th and last evaluable patient has completed their day 42 visit in its Phase 2b/3 study of NRX-101, the Company's patented combination of the NMDA antagonist D-cycloserine and lurasidone, in Suicidal Treatment Resistant Bipolar Depression. The database is being cleaned, finalized, and locked; statistical analysis will then be performed, with top-line data to follow shortly thereafter. As previously disclosed, positive data from this trial triggers a milestone payment from Alvogen. Alvogen will then be responsible for further development and commercialization costs for this program.
NRX-101 has been awarded Breakthrough Therapy Designation, Fast Track Designation, a Biomarker Letter of Support, and a Special Protocol Agreement by the FDA for treatment of suicidal bipolar depression. It is the only oral medication to have demonstrated reduced suicidal ideation in patients with bipolar depression, a lethal disease that claims the lives of one in five who live with it.
"This is the first clinical trial, to the company's knowledge, conducted among patients with suicidal bipolar depression in the outpatient setting. Our previous trial measured the ability of NRX-101 to maintain the anti-depressant and anti-suicidal effect of ketamine administered in the hospital setting. These patients, whose clinical need is urgent and extraordinary have routinely been excluded from the clinical trials of all previously-known anti-depressant drugs. said Dr. Jonathan Javitt, Founder, Chairman and Chief Scientist of NRx Pharmaceuticals. Although there were patients whose depression worsened and required hospitalization (we don't yet know whether they were on NRX-101 or comparator), patient safety was maintained, and no trial participant suffered a serious unexpected adverse outcome. Our thanks go out to our investigators, clinics, partners and, most importantly, our amazing patients and their families for seeing this study through to this important milestone," "
The Phase 2b/3 trial (www.clinicaltrials.gov NCT 03395392) is a randomized, prospective, multicenter, double-blind study comparing NRX-101 to lurasidone over six weeks. The Principal Investigator is Prof. Andrew Nierenberg of Harvard Massachusetts General Hospital. The primary efficacy endpoint is reduction in depression as measured on the MADRS scale and the secondary endpoint is reduction of suicidal ideation as measured by the Clinical Global Impression Suicidality Scale (CGI-SS). As previously disclosed, treatment compliance and concordance of local raters to central raters scores was in excess of 94%, well above the industry standard that is normally seen in CNS trials.
Top-line results are expected around the end of this quarter.
About NRx Pharmaceuticals
NRx Pharmaceuticals is a clinical-stage biopharmaceutical company developing therapeutics based on its NMDA platform for the treatment of central nervous system disorders, specifically suicidal bipolar depression, chronic pain and PTSD. The Company is developing NRX-101, an FDA-designated investigational Breakthrough Therapy for suicidal treatment-resistant bipolar depression and chronic pain. NRx has partnered with Alvogen and Lotus around the development and marketing of NRX-101 for the treatment of suicidal bipolar depression. NRX-101 additionally has potential to act as a non-opioid treatment for chronic pain, as well as a treatment for complicated UTI.
NRx has recently announced plans to submit a New Drug Application for HTX-100 (IV ketamine), through Hope Therapeutics, in the treatment of suicidal depression, based on results of well-controlled clinical trials conducted under the auspices of the US National Institutes of Health and newly obtained data from French health authorities, licensed under a data sharing agreement. NRx was awarded Fast Track Designation for development of ketamine (NRX-100) by the US FDA as part of a protocol to treat patients with acute suicidality.
About HOPE Therapeutics, Inc.
HOPE Therapeutics, Inc. (www.hopetherapeutics.com) is a Specialty Pharmaceutical Company, wholly-owned by NRX Pharmaceuticals focused on development and marketing of an FDA-approved form of intravenous ketamine for the treatment of acute suicidality and depression together with a digital therapeutic-enabled platform designed to augment and preserve the clinical benefit of NMDA-targeted drug therapy.
Notice Regarding Forward-Looking Statements
The information contained herein includes forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended. These statements include, among others, statements regarding the proposed public offering and the timing and the use of the proceeds from the offering. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as "may," "will," "should," "would," "expect," "plan," "believe," "intend," "look forward," and other similar expressions among others. These statements relate to future events or to the Company's future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause the Company's actual results to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the Company's control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects the Company's current views with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to the Company's operations, results of operations, growth strategy and liquidity. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's most recent Annual Report on Form 10-K and other filings with the Securities and Exchange Commission. Investors and security holders are urged to read these documents free of charge on the SEC's website at http://www.sec.gov. Except as may be required by applicable law, The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, whether as a result of new information, future events or otherwise.
https://c212.net/c/img/favicon.png?sn=CL51263&sd=2024-03-04 View original content to download multimedia:https://www.prnewswire.com/news-releases/nrx-pharmaceuticals-nasdaq-nrxp-announces-last-patient-last-visit-in-its-phase-2b3-trial-of-nrx-101-in-suicidal-treatment-resistant-bipolar-depression-302078041.html
SOURCE NRx Pharmaceuticals, Inc.
$LBRG through its subsidiary Growhouse Nutraceuticals Ltd., is actively bolstering its revenue with strategic acquisitions in the health and wellness domain.https://www.reddit.com/r/10xPennyStocks/comments/1b7923j/ladybug_lbrg_announces_acquisition_of_ecommerce/
Silynxcom Ltd (NYSE- Amer: $SYNX) stock is continuing its bullish ways
https://reddit.com/r/stockstobuytoday/comments/1b83ijm/silynxcom_ltd_nyse_amer_synx_stock_is_continuing/
MRAI...............GGE................MULN...................https://stockcharts.com/h-sc/ui?s=MULN&p=D&yr=0&mn=3&dy=0&id=p11960084343
https://stockcharts.com/h-sc/ui?s=GGE&p=D&yr=0&mn=3&dy=0&id=p11960084343
https://stockcharts.com/h-sc/ui?s=MRAI&p=D&yr=0&mn=3&dy=0&id=p11960084343
$SYNX Silynxcom Receives $400,000 Follow Up Order from a Leading Global Defense Company
https://finance.yahoo.com/news/silynxcom-receives-400-000-order-140000351.html
Ladybug $LBRG Announces Acquisition of E-Commerce Generating $2.4 Million Annual Revenue https://www.reddit.com/r/10xPennyStocks/comments/1b7923j/ladybug_lbrg_announces_acquisition_of_ecommerce/
$DFCO's CEO talks big new contracts in new interview! Who knew the heat pump market was so big in Europe and that is only part of what Dalrada does? They have multiple revenue streams and on track for cash flow positive this year!
Marpai Inc (NASDAQ: $MRAI) AI-based business model to lower costs while providing better healthcare options for employees and their families has piqued the interest of many investors.
Best Growth Stock's full report breaks through the noise and offers an extensive comprehensive analysis of Marpai’s current and anticipated financial results, potential catalysts, share structure, cash position, and much more.
Access this full analysis free: https://bestgrowthstocks.com/access-mrai-analysis/
Fisker Inc’s (NYSE: $FSR) possible $400 million investment from Nissan has piqued the interest of many EV investors.
Access this full analysis free: https://bestgrowthstocks.com/access-fisker-analysis/
$SYNX is proud to announce that it has developed an innovative new product designed for dogs in militaries. https://finance.yahoo.com/news/silynxcom-unveils-groundbreaking-headset-military-140000139.html
JAGX......MULN..............................................https://stockcharts.com/h-sc/ui?s=JAGX&p=D&yr=0&mn=2&dy=12&id=p84071410134
https://stockcharts.com/h-sc/ui?s=MULN&p=D&yr=0&mn=2&dy=12&id=p84071410134
$AGBA - AGBA Group Holding Limited has the potential to unlock significant shareholder value!
https://www.tiktok.com/@mahinagency/video/7340661285522066689
$TWOH -- NAVIGATING THE FUTURE: THE EVOLUTION OF MICRO MERCHANT FOOD WHOLESALERS https://twohandsgroup.com/blog/micro-merchant-wholesalers-evolution
$TWOH Two Hands Corporation: Elevating Canada's Micro Merchant Wholesaler Landscape https://finance.yahoo.com/news/two-hands-corporation-elevating-canadas-130000053.html
$SYNX -- Enforce Tac 2024: Messer Waffenhandel mit Robotican, Silynx und Thirdeye Systems
$CETX News: Cemtrex Issues Shareholder Letter and Provides Corporate Update
Completed Restructuring in 2023 Now Positions AIS and Vicon Segments for Continued Revenue Growth and Expanded Operating Profitability
Brooklyn, NY, Feb. 28, 2024 (GLOBE NEWSWIRE) -- - Cemtrex Inc. (NASDAQ: CETX, CETXP), an advanced security technology and industrial services company, today issued a letter to shareholders from Chairman and CEO Saagar Govil.
To the Shareholders of Cemtrex, Inc.,
I wanted to provide you with a detailed update on Cemtrex’s activities over the last several months. If you have been following our progress closely then you will know that we have made many changes to our organization with the hope that we will generate attractive returns for all of you as we go forward. I also wanted to take this opportunity to talk a little bit more in depth about our Company in a way that might provide additional insight into why management has made some of the decisions we have, and how management views the current opportunities in our portfolio.
Over the last five years we have made a number of different investments. Some have proven to be quite fruitful while others, unfortunately, have not led to great results. We cannot change the missteps we have taken, but we have certainly learned from them and learned how to avoid them in the future. While we remain bullish in the emerging opportunities that Cemtrex invested in over the last five years, like Virtual Reality and SmartDesk, it became readily apparent that we could not effectively drive the best outcomes with these long-term investments due to the enormous cash requirements and operating losses that would be required to see these through. Private companies have certain luxuries that public companies do not have when it comes to building startups, particularly in rising interest rate environments. As a result, we made the difficult but ultimately correct decision to exit these businesses.
Looking ahead, we can confidently say that the path we are on today is clearer than ever, with the highest assurance of success that we have had since the Company’s inception. But what does success mean? For us, a company over the long term should be able to generate a higher return with its cash than would be possible by investing it in the S&P 500 index. Everything starts with this fundamental premise. Sadly, today there are many public companies that do not meet this test, including ours in recent years. Over the last ten years, despite making several smart decisions, we made some unforced errors which resulted in relinquishing any positive returns in our common stock that could have been realized. However, despite these setbacks we remain well poised for a positive turnaround on this front. Based on the numerous changes over the last twenty four months and restructuring of our business that we undertook in November of 2022, I am confident that we are on the right track to start consistently driving above average returns. Let’s dive into why that is the case:
With the restructuring completed Cemtrex owns two great businesses: Vicon Industries, Inc. (“Vicon”) which comprises our Security segment, and Advanced Industrial Services, Inc. (“AIS”) which comprises our Industrial segment.
When we make an investment, we primarily look at two measures of capital return efficiency. The first is with respect to our investment. What is the cash-on-cash return of the investment over its life compared to the S&P 500? Additionally, we look at, on an annual basis, what is the Annual Net Income against the starting FY Shareholder’s Equity in the business?
We acquired AIS during our FY 2016 for a total purchase price of $7,500,000. Out of that purchase price, Cemtrex contributed $1,000,000 of equity, which was paid in the form of Cemtrex stock. The balance of the purchase price was financed through debt. Looking at the Net Income of the business, excluding the unusual benefits of COVID-19 relief programs like PPP that took place in 2021, the cumulative return on that investment over the eight years we have owned AIS has been $8,628,084 or 863%. When that cumulative return is averaged over the 8 years ownership it represents a 108% annual return on Cemtrex’s invested capital.
Furthermore, when we look at our second measure for this business, the annual return on equity, we see additional encouraging results. The annual return on beginning shareholder’s equity for AIS, on average, over the last 8 years, again excluding PPP benefits in 2021, has been approximately 35%. This important measure encourages management to continue investing its equity into this business to drive outsized returns. Additional factors that make AIS an attractive business are: 1) approximately 70% of our sales come from repeat customers we do business with; 2) attractive 30%+ gross margins that we see further opportunity to drive higher as we grow the business; 3) the macro-economic factors in the U.S. that are driving growth, including increased infrastructure spending and reshoring of manufacturing.
For FY 2023, AIS produced strong results, with sales reaching $25 million compared to $21.2 million for the prior year, an increase of 18%. Additionally, operating income increased from $.6 million in FY 2022 to $3.1 million in FY 2023, representing a 400% increase in operating earnings for the period.
Regarding our Security segment, let’s focus on our investment in Vicon of which we own 95%. Cemtrex has invested approximately $22.95 million of its own cash into Vicon, as debt and equity, to date over the five years of ownership, including the cost of acquiring the shares of the business as well as additional investments made into the company to grow it. At the time our initial investment was made the market cap of the company was approximately $5.5 million. Today, with the company doing $34.7 million in annual revenue and three sequential quarters of operating profit in FY 2023, we can conservatively estimate the enterprise value of Vicon to be substantially higher than when we made our investment and our return on equity, when annualized over the 5 years of ownership, far exceeds the competing return on the S&P 500.
In FY 2023, Vicon produced significantly better results, with sales growing from $23.8 million in FY 2022 to $34.7 million in FY 2023, an increase of 46%. Gross Profit improved from $8.5 million in FY 2022 to $15.6 million in FY 2023, an increase of 85%. The operating loss at Vicon was reduced from $6.1 million in FY 2022 to $0.6 million in FY 2023, a reduction of 92%, and the Company has had an operating profit three of the last four quarters.
The exciting part is that we believe relative to our current investment, limited additional capital, if any, will be required on Cemtrex’s behalf to drive further growth at Vicon. Based on the continued opportunity for growth, we believe that Vicon has tremendous potential to increase its enterprise value over the next five years that would maintain or exceed the annual return on our capital. This will be accomplished primarily by driving further topline growth, increasing operating profits, and scaling Annual Recurring Revenue (“ARR”) products that we believe can drive multiple expansion.
In our segment reporting we now carve out our Corporate costs, essentially the costs to manage these portfolio companies and the costs of being a public company, as a separate segment so that it is easier for our shareholders to better ascertain the underlying performance of the businesses we own. The Corporate costs today reduce our operating income meaningfully, but as we scale the business these costs will continue to remain at low levels relative to our earnings.
As legendary investor Peter Lynch said, “Often, there is no correlation between the success of a company’s operations and the success of its stock over a few months or even a few years. In the long term, there is a 100% correlation between the success of a company and the success of its stock.” Our goal going forward is to leverage our capital in a way to drive excellent operating results and thus deliver exceptional returns on our investments over time. We remain confident that as we stay on this path the consistent results in the business will begin to be reflected in our stock.
All the above certainly doesn’t summarize all the accomplishments that have taken place within our Company this past year. We have added a number of talented employees, restructured some of our debt to give us greater flexibility for growth, completed an important acquisition at AIS, and launched several exciting products at Vicon that will set it on a path for long term success for years to come. We feel, based on the results above, that FY 2023 represents a key turning point for us, as we have a renewed focus, clarity, and resolve to deliver exceptional results going forward.
Sincerely,
Saagar Govil
Chairman and Chief Executive Officer
About Cemtrex
Cemtrex Inc. (CETX) is a company that owns two operating subsidiaries: Vicon Industries Inc and Advanced Industrial Services Inc.
Vicon Industries, a subsidiary of Cemtrex Inc., is a global leader in advanced security and surveillance technology to safeguard businesses, schools, municipalities, hospitals and cities. Since 1967, Vicon delivers mission-critical security surveillance systems, specializing in engineering complete security solutions that simplify deployment, operation and ongoing maintenance. Vicon provides security solutions for some of the largest municipalities and businesses in the U.S. and around the world, offering a wide range of cutting-edge and compliant security technologies, from AI-driven video analytics to fully integrated access control solutions. For more information visit www.vicon-security.com
AIS – Advanced Industrial Services, a subsidiary of Cemtrex, Inc., is a premier provider of industrial contracting services including millwrighting, rigging, piping, electrical, welding. AIS Installs high precision equipment in a wide variety of industrial markets including automotive, printing & graphics, industrial automation, packaging, and chemicals. AIS owns and operates a modern fleet of custom designed specialty equipment to assure safe and quick installation of your production equipment. Our talented staff participates in recurring instructional training, provided to ensure that the most current industry methods are being utilized to provide an efficient and safe working environment. For more information visit www.ais-york.com
For more information visit http://www.cemtrex.com.
Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to the closing of the offering, gross proceeds from the offering, our new product offerings, expected use of proceeds, or any proposed fundraising activities. These forward-looking statements are based on management’s current expectations and are subject to certain risks and uncertainties that could cause actual results to differ materially from those set forth in or implied by such forward looking statements. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. These risks and uncertainties are discussed under the heading “Risk Factors” contained in our Form 10-K filed with the Securities and Exchange Commission. All information in this press release is as of the date of the release and we undertake no duty to update this information unless required by law.
https://www.globenewswire.com/newsroom/ti?nf=OTA1NDkzNyM2MTEyMTUwIzIwNDk3MDg=
https://ml.globenewswire.com/media/YmVkYTQxMGItNDhhMy00MjFhLWJhMTEtZDM5MzJhMmQzNjcwLTEwNjEyNzk=/tiny/Cemtrex-Inc-.png
Investor Relations
Chris Tyson
Executive Vice President – MZ North America
Direct: 949-491-8235
CETX@mzgroup.us
www.mzgroup.us
Source: Cemtrex Inc.
#BreakingNews: Silynxcom $SYNX Unveils Groundbreaking Headset for Military Dogs, Offering Unparalleled Protection and Communication
https://www.reddit.com/r/10xPennyStocks/comments/1b33p1v/breakingnews_silynxcom_synx_unveils/
Silynxcom $SYNX Receives $400,000 Follow Up Order from a Leading Global Defense Company https://www.reddit.com/r/SmallCapGrowth/comments/1b31hj6/silynxcom_synx_receives_400000_follow_up_order/
$CBDW — Future-Proof Your Business: Will you Embrace ChatBots & AI or Risk Falling Behind in the Digital Revolution https://cbdw.ai/future-proof-your-business-will-you-embrace-chatbots-ai-or-risk-falling-behind-in-the-digital-revolution/
1606 Corp. $CBDW Recaps Major Accomplishments in February & Provides Outlook For March
https://www.reddit.com/r/Shortsqueeze/comments/1b2zt92/1606_corp_cbdw_recaps_major_accomplishments_in/
$SYNX Silynxcom Delivers $280,000 Repeat Order from Military Customer https://finance.yahoo.com/news/silynxcom-delivers-280-000-repeat-133000151.html
Ford to acquire/partner with otc micro cap CRTG?
CRTG Eyes Major Corporate Shift, Teases Revolutionary Battery Tech & Potential Ford Partnership
CRTG is on the brink of unveiling a game-changing partnership or merger, alongside its revolutionary silicon anode battery technology. Learn how these developments could redefine the industry.As the business world holds its breath, CRTG is on the verge of announcing a significant corporate development, speculated to be a groundbreaking partnership or a strategic merger, causing its stock to soar in anticipation. This news comes alongside the company's innovative strides in battery technology, potentially setting a new industry standard. The postponed shareholder call, initially set for January 11, hints at the imminent finalization of this deal, promising to shake the tech and automotive sectors.
Revolutionary Battery Technology in the Spotlight
CRTG has made headlines with its pioneering silicon anode battery technology, capable of charging batteries to 80% capacity in a mere 6 minutes. This advancement is not only a game-changer in terms of charging speed but also in efficiency, boasting over 500 Wh/Kg. This figure effectively doubles the performance of Tesla's current batteries, positioning CRTG as a formidable contender in the battery technology race. The potential of this technology was further underscored in a podcast on October 26, 2023, where CEO Matt Kappers revealed that automotive giant Ford is set to test this new anode, marking a significant milestone for CRTG and the broader industry....
more here: https://bnnbreaking.com/finance-nav/crtg-eyes-major-corporate-shift-teases-revolutionary-battery-tech-potential-ford-partnership
video link: https://thecoretecgroup.com/technology/endurion/
$CBDW good buying opportunity here https://schrts.co/MgfgHVHk
Business Investor Overview Feb 2024 | The Power Of AI Chatbots $CBDW
Hey Glen can you look into LSEB I think you might like it
$SYNX Silynxcom Delivers Huge Repeat Order From Customer https://dexwirenews.com/silynxcom-ltd-nyse-synx-delivers-280k-worth-of-military-gear-for-repeat-order/
$TWOH STRATEGIC EXPANSION UNVEILED: HOW THE TWOH ACQUISITION PLAYBOOK WILL TRANSFORM FOOD DISTRIBUTION IN CANADA
https://twohandsgroup.com/blog/strategic-expansion-twoh-acquisition-playbook
ANTE 1.08 lv2 super thin moves on sir
Followers
|
1524
|
Posters
|
|
Posts (Today)
|
5
|
Posts (Total)
|
84662
|
Created
|
03/06/15
|
Type
|
Free
|
Moderator PennyMaster | |||
Assistants Golden Cross hstang04 Garyst BLULLISH |
*DISCLAIMER*
•The Board Moderator and The Board Assistants herewith, are not licensed brokers and assume NO responsibility for the actions, investment decisions, or messages posted on this forum.
• We do NOT recommend that anyone buy or sell any securities posted herewith. Any trade entered into risks the possibility of losing the funds invested.
• Always do your own due diligence with any stock you may consider buying and never invest more than you are willing to lose.
• Stocks mentioned here may or may not be held by members posting on this board.
• There are no guarantees when buying or selling any security.
Posts Today
|
5
|
Posts (Total)
|
84662
|
Posters
|
|
Moderator
|
|
Assistants
|
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |